Sector Stalwart Appalled At Lack Of UK Investor Interest In Biotech
Executive Summary
Ali Mortazavi, CEO of e-therapeutics, says the RNAi specialist is delisting from AIM and describes the UK markets as “completely broken and closed” to biotech firms.